Free Trial
NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Price, News & Analysis

Akari Therapeutics logo
$1.18 +0.03 (+2.16%)
As of 07/3/2025 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Akari Therapeutics Stock (NASDAQ:AKTX)

Key Stats

Today's Range
$1.14
$1.17
50-Day Range
$1.09
$1.46
52-Week Range
$0.85
$4.40
Volume
2,252 shs
Average Volume
31,312 shs
Market Capitalization
$37.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Akari Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
20th Percentile Overall Score

AKTX MarketRank™: 

Akari Therapeutics scored higher than 20% of companies evaluated by MarketBeat, and ranked 2569th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Akari Therapeutics.

  • Percentage of Shares Shorted

    0.11% of the float of Akari Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akari Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Akari Therapeutics has recently decreased by 72.77%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Akari Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Akari Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.11% of the float of Akari Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akari Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Akari Therapeutics has recently decreased by 72.77%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Akari Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Akari Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,120.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    38.10% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 5.06% of the stock of Akari Therapeutics is held by institutions.

  • Read more about Akari Therapeutics' insider trading history.
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Akari Therapeutics, Plc (AKTX) - Yahoo Finance
Akari Therapeutics Plc (AKTX) Stock Forecasts
See More Headlines

AKTX Stock Analysis - Frequently Asked Questions

Akari Therapeutics' stock was trading at $1.22 at the start of the year. Since then, AKTX stock has decreased by 3.3% and is now trading at $1.18.

Akari Therapeutics PLC (NASDAQ:AKTX) released its earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) EPS for the quarter, missing the consensus estimate of ($2.80) by $5.00.

Akari Therapeutics shares reverse split on the morning of Thursday, August 17th 2023.The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akari Therapeutics investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), Meta Platforms (META) and GE Aerospace (GE).

Company Calendar

Last Earnings
3/31/2020
Today
7/03/2025
Next Earnings (Estimated)
8/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AKTX
Employees
9
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.79 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.84 per share
Price / Book
1.40

Miscellaneous

Free Float
19,917,000
Market Cap
$37.97 million
Optionable
Not Optionable
Beta
0.21
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:AKTX) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners